December 7th 2017, 12:52am
The combination use of Herceptin plus standard adjuvant chemotherapy does not improve outcomes in women with HER2-low breast cancer.
December 6th 2017, 11:52pm
For women with early-stage breast cancer who are receiving chemotherapy, shortening the time between treatment cycles or administering the agents sequentially may reduce disease recurrence and mortality compared with standard chemotherapy regimens.
Challenging Assumptions About Cancer and Its Treatments
Sharing Stories of Survivorship
Perioperative Therapy in Resectable NSCLC: The Drive for a Cure
How My Daughter Stood Up to Breast Cancer